--- title: "Shanghai Henlius Biotech (2696) stock and investor profile" url: "https://aibio.space/companies/shanghai-henlius-biotech/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Shanghai Henlius Biotech, Inc. (HKEX: 2696), China. The directory classifies it as Pharmaceuticals: Major." --- 2696 Shanghai Henlius Biotech, Inc. HKEX · China # Shanghai Henlius Biotech (2696) news Shanghai Henlius Biotech, Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2696, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest Shanghai Henlius Biotech news We have not published a story on Shanghai Henlius Biotech yet. When there is news, it will appear here. ## Shanghai Henlius Biotech at a glance - **Ticker**: 2696 - **Listing**: HKEX - **Country**: China ### Related companies - [Guizhou Xinbang Pharmaceutical Co.](https://aibio.space/companies/guizhou-xinbang-pharmaceutical/) SZSE: 002390 - [Cheng Du Sheng Nuo Biotec Co.](https://aibio.space/companies/cheng-du-sheng-nuo-biotec/) SSE: 688117 - [Shanghai Allist Pharmaceuticals Co.](https://aibio.space/companies/shanghai-allist-pharmaceuticals/) SSE: 688578 - [Sunflower Pharmaceutical Group Co.](https://aibio.space/companies/sunflower-pharmaceutical/) SZSE: 002737 - [Beijing Science Sun Pharmaceutical Co.](https://aibio.space/companies/beijing-science-sun-pharmaceutical/) SZSE: 300485 - [Shandong Boan Biotechnology Company., Limited.](https://aibio.space/companies/shandong-boan-biotechnology/) HKEX: 6955 - [Ningbo Menovo Pharmaceutical Co.](https://aibio.space/companies/ningbo-menovo-pharmaceutical/) SSE: 603538 - [Zhejiang Shapuaisi Pharmaceutical Co.](https://aibio.space/companies/zhejiang-shapuaisi-pharmaceutical/) SSE: 603168 ### Also on HKEX - [China Biotech Services Holdings](https://aibio.space/companies/china-biotech-services/) 8037 - [Genscript Biotech](https://aibio.space/companies/genscript-biotech/) 1548 - [CARsgen Therapeutics Holdings](https://aibio.space/companies/carsgen-therapeutics/) 2171 - [XtalPi Holdings](https://aibio.space/companies/xtalpi/) 2228 - [Suzhou Ribo Life Science Co.](https://aibio.space/companies/suzhou-ribo-life-science/) 6938 - [Fujian Haixi Pharmaceuticals Co.](https://aibio.space/companies/fujian-haixi-pharmaceuticals/) 2637 ## Questions about Shanghai Henlius Biotech What is the ticker symbol of Shanghai Henlius Biotech? Shanghai Henlius Biotech, Inc. trades under the ticker 2696 on HKEX. Where is Shanghai Henlius Biotech listed? Shanghai Henlius Biotech, Inc. is listed on HKEX. Our directory also records these other listings: LSX:A2PRXP. Which country or territory is Shanghai Henlius Biotech listed under? Our directory records Shanghai Henlius Biotech, Inc. under China. What does Shanghai Henlius Biotech do? Our directory classifies Shanghai Henlius Biotech, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Shanghai Henlius Biotech? The ISIN recorded for Shanghai Henlius Biotech, Inc. is CNE100003N76. Does aibio.space cover Shanghai Henlius Biotech? aibio.space lists Shanghai Henlius Biotech, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Which companies are similar to Shanghai Henlius Biotech? Companies in our directory listed in the same country and business area as Shanghai Henlius Biotech: Guizhou Xinbang Pharmaceutical Co., Cheng Du Sheng Nuo Biotec Co., Shanghai Allist Pharmaceuticals Co., Sunflower Pharmaceutical Group Co., Beijing Science Sun Pharmaceutical Co., Shandong Boan Biotechnology Company., Limited.. ## Investor discussion: Shanghai Henlius Biotech Members talk about Shanghai Henlius Biotech (2696). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Shanghai Henlius Biotech, newest first. Each line links the filing it comes from. 1. 2026-04-24 Financings Share or debt issue: (1) ANNUAL REPORT 2025 (2) BOARD REPORT 2025 (3) BOARD OF SUPERVISORS REPORT 2025 (4) FINAL ACCOUNTS REPORT 2025 (5) PROFIT DISTRIBUTION PROPOSAL 2025 (6) RE-APPOINTMENT OF AUDITORS (7) REMUNERATIONS OF THE FULL-TIME EXECUTIVE DIRECTOR FOR THE YEAR 2025 (8) GRANT OF GENERAL MANDATE TO ISSUE SHARES (9) GRANT OF GENERAL MANDATE TO REPURCHASE H SHARES AND NOTICE OF AGM. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042401959.pdf) 2. 2025-04-15 Financings Share or debt issue: ANNUAL GENERAL MEETING; RE-APPOINTMENT OF AUDITORS; GRANT OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE H SHARES; PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION; NOTICES OF AGM. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0415/2025041500525.pdf) 3. 2025-01-22 Listings Trading status: JOINT ANNOUNCEMENT - (1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING AND THE H SHAREHOLDERS' CLASS MEETING RELATING TO THE PROPOSED PRIVATISATION OF HENLIUS BY FOSUN NEW MEDICINE BY WAY OF MERGER BY ABSORPTION OF HENLIUS AND (2) TERMINATION OF THE MERGER. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0122/2025012200662.pdf) 4. 2025-01-10 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0110/2025011000368.pdf) 5. 2025-01-09 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0109/2025010900402.pdf) 6. 2025-01-08 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0108/2025010800215.pdf) 7. 2025-01-08 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0108/2025010800216.pdf) 8. 2025-01-03 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0103/2025010301601.pdf) 9. 2025-01-03 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0103/2025010301600.pdf) 10. 2025-01-03 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0103/2025010301599.pdf) 11. 2025-01-02 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0102/2025010202502.pdf) 12. 2025-01-02 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0102/2025010202501.pdf) 13. 2025-01-02 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0102/2025010202503.pdf) 14. 2024-12-31 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1231/2024123100738.pdf) 15. 2024-12-31 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1231/2024123100737.pdf) 16. 2024-12-31 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1231/2024123100739.pdf) 17. 2024-12-30 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1230/2024123000526.pdf) 18. 2024-12-30 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1230/2024123000525.pdf) 19. 2024-12-30 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1230/2024123000527.pdf) 20. 2024-12-27 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1227/2024122700389.pdf) 21. 2024-12-24 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1224/2024122400361.pdf) 22. 2024-12-23 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1223/2024122300743.pdf) 23. 2024-12-22 Mergers Transaction under the Listing Rules: ELECTION FORM FOR THE CASH ALTERNATIVE OR THE SHARE ALTERNATIVE. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1222/2024122200029.pdf) 24. 2024-12-22 Listings Trading status: (1) PROPOSED PRIVATISATION OF HENLIUS BY FOSUN NEW MEDICINE BY WAY OF MERGER BY ABSORPTION OF HENLIUS (2) PROPOSED WITHDRAWAL OF LISTING OF THE H SHARES OF HENLIUS (3) NOTICE OF THE EXTRAORDINARY GENERAL MEETING AND (4) NOTICE OF THE H SHAREHOLDERS' CLASS MEETING. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1222/2024122200027.pdf) 25. 2024-12-22 Listings Trading status: JOINT ANNOUNCEMENT - DESPATCH OF COMPOSITE DOCUMENT IN RELATION TO THE PROPOSED PRIVATISATION OF HENLIUS BY FOSUN NEW MEDICINE BY WAY OF MERGER BY ABSORPTION OF HENLIUS. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1222/2024122200025.pdf) 26. 2024-12-20 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1220/2024122000532.pdf) 27. 2024-12-19 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1219/2024121900548.pdf) 28. 2024-12-18 Mergers Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1218/2024121800794.pdf) 29. 2024-12-16 Listings Trading status: JOINT ANNOUNCEMENT - FULFILMENT OF THE PRE-CONDITIONS OF THE PROPOSED PRE-CONDITIONAL PRIVATISATION OF HENLIUS BY FOSUN NEW MEDICINE BY WAY OF MERGER BY ABSORPTION OF HENLIUS. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1216/2024121600988.pdf) 30. 2024-11-22 Listings Trading status: JOINT ANNOUNCEMENT - PROGRESS UPDATE IN RELATION TO THE PRE-CONDITIONAL PRIVATISATION OF HENLIUS BY FOSUN NEW MEDICINE BY WAY OF MERGER BY ABSORPTION OF HENLIUS. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1122/2024112201174.pdf) ## Press releases Headlines of Shanghai Henlius Biotech's own announcements, newest first. Each opens the full release on the newswire that carried it. 1. 2026-10-27 PR Newswire [Henlius reports positive results from ASTRIDE U.S. bridging study for serplulimab in combination with chemotherapy for first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC)](https://www.prnewswire.com/news-releases/henlius-reports-positive-results-from-astride-us-bridging-study-for-serplulimab-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-extensive-stage-small-cell-lung-cancer-es-sclc-302920457.html) 2. 2026-09-30 HKEXnews [(1) CHANGES IN NON-EXECUTIVE DIRECTOR AND INDEPENDENT NON-EXECUTIVE DIRECTOR (2) APPOINTMENT OF CHAIRMAN OF THE BOARD AND CHANGES IN COMPOSITION OF THE BOARD COMMITTEES](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0930/2026093001245.pdf) 3. 2026-09-23 HKEXnews [VOLUNTARY ANNOUNCEMENT - COLLABORATION AND LICENSE AGREEMENT WITH AMBERSTONE FOR TWO T CELL ENGAGER PRODUCTS](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0923/2026092300674.pdf) 4. 2026-09-11 HKEXnews [VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR 120 MG (1.7 ML) PER VIAL STRENGTH OF BIOSIMILAR OF DENOSUMAB HLX14 (RECOMBINANT ANTI-RANKL HUMAN MONOCLONAL ANTIBODY INJECTION) HAS BEEN ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA)](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0911/2026091100302.pdf) 5. 2026-09-07 HKEXnews [VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE LIST OF ELIGIBLE SECURITIES OF HONG KONG STOCK CONNECT](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0907/2026090700185.pdf) 6. 2026-08-21 HKEXnews [VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY AS A CONSTITUENT STOCK OF HANG SENG COMPOSITE INDEX](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0821/2026082101181.pdf) 7. 2026-08-21 HKEXnews [INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026 AND CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0821/2026082101149.pdf) 8. 2026-08-17 HKEXnews [INSIDE INFORMATION ANNOUNCEMENT - STRATEGIC COLLABORATION WITH SANDOZ](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081700129.pdf) 9. 2026-07-31 HKEXnews [VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR CLINICAL TRIAL OF HLX43 FOR INJECTION (AN ANTIBODY-DRUG CONJUGATE TARGETING PD-L1) IN COMBINATION WITH BEVACIZUMAB WITH OR WITHOUT CHEMOTHERAPY FOR THE TREATMENT OF ADVANCED/METASTATIC SOLID TUMOURS HAS BEEN APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0731/2026073100326.pdf) 10. 2026-07-30 HKEXnews [VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX3902 INJECTION (STEAP1xCD3xCD28 TRISPECIFIC ANTIBODY) FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER ADVANCED SOLID TUMORS IN CHINESE MAINLAND](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0730/2026073000930.pdf) 11. 2026-07-17 HKEXnews [GRANTS OF OPTIONS AND RSUS](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0717/2026071701565.pdf) 12. 2026-07-16 HKEXnews [VOLUNTARY ANNOUNCEMENT - THE GLOBAL FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTI-CENTER PHASE 1 CLINICAL STUDY OF NIVOLUMAB BIOSIMILAR HLX18 (RECOMBINANT ANTI-PD-1 HUMANIZED MONOCLONAL ANTIBODY INJECTION) IN PATIENTS WITH MULTIPLE RESECTED SOLID TUMORS IN CHINESE MAINLAND](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0716/2026071600215.pdf) 13. 2026-07-10 HKEXnews [VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE PHASE 1 CLINICAL TRIAL OF HLX37 (RECOMBINANT HUMANISED ANTI-PD-L1 AND ANTI-VEGF BISPECIFIC ANTIBODY) IN COMBINATION WITH CHEMOTHERAPY OR HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) FOR THE TREATMENT OF ADVANCED/METASTATIC SOLID TUMOURS HAS BEEN APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0710/2026071000245.pdf) 14. 2026-07-08 HKEXnews [VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF CETUXIMAB INJECTION BIOSIMILAR HLX05-N (RECOMBINANT ANTI-EGFR CHIMERIC HUMAN-MURINE MONOCLONAL ANTIBODY INJECTION) IN PATIENTS WITH METASTATIC COLORECTAL CANCER (mCRC) IN CHINESE MAINLAND](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0708/2026070800517.pdf) 15. 2026-06-30 HKEXnews [VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX48 FOR INJECTION (AN ANTIBODY-DRUG CONJUGATE TARGETING EGFR AND C-MET) FOR THE TREATMENT OF ADVANCED/ METASTATIC SOLID TUMORS IN CHINESE MAINLAND](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063001292.pdf) 16. 2026-06-25 HKEXnews [VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT IN THE UNITED STATES HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTER PHASE 1 CLINICAL STUDY OF IPILIMUMAB BIOSIMILAR HLX13 (RECOMBINANT ANTI-CTLA-4 FULLY HUMAN MONOCLONAL ANTIBODY INJECTION) AS A FIRST-LINE TREATMENT FOR PATIENTS WITH UNRESECTABLE ADVANCED HEPATOCELLULAR CARCINOMA (HCC)](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0625/2026062501162.pdf) 17. 2026-06-25 HKEXnews [VOLUNTARY ANNOUNCEMENT - THE EUROPEAN COMMISSION (EC) HAS APPROVED A NEW INDICATION FOR SERPLULIMAB INJECTION (TRADE NAME IN CHINESE MAINLAND: HANSIZHUANG; TRADE NAME IN THE EUROPEAN UNION: HETRONIFLY), IN COMBINATION WITH CHEMOTHERAPY INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC SQUAMOUS NON-SMALL CELL LUNG CARCINOMA (sqNSCLC)](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0625/2026062501082.pdf) 18. 2026-06-17 HKEXnews [VOLUNTARY ANNOUNCEMENT - THE PHASE 1 CLINICAL TRIAL OF HLX3902 INJECTION (STEAP1xCD3xCD28 TRISPECIFIC ANTIBODY) FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER ADVANCED SOLID TUMORS HAS BEEN APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0617/2026061700916.pdf) 19. 2026-06-17 HKEXnews [VOLUNTARY ANNOUNCEMENT - HANBEIYOU (PERTUZUMAB INJECTION) PASSING GMP COMPLIANCE INSPECTION](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0617/2026061700852.pdf) 20. 2026-06-16 HKEXnews [VOLUNTARY ANNOUNCEMENT - THE PHASE 2 CLINICAL TRIAL OF HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) IN COMBINATION WITH HANSIZHUANG (SERPLULIMAB INJECTION) FOR NEOADJUVANT THERAPY OF NON-SMALL CELL LUNG CANCER (NSCLC) APPROVED TO COMMENCE IN AUSTRALIA](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0616/2026061600910.pdf) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open HKEX:2696 on TradingView](https://www.tradingview.com/symbols/HKEX-2696/). ## Listing details Shanghai Henlius Biotech, Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2696, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Shanghai Henlius Biotech, Inc. - **Ticker**: 2696 - **Listing**: HKEX - **Country or territory**: China - **Business scope**: Pharmaceuticals: Major - **ISIN**: CNE100003N76 - **Other listed symbols**: LSX:A2PRXP - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/HKEX-2696/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/shanghai-henlius-biotech/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Shanghai Henlius Biotech (2696) stock and investor profile", 2026-10-31, https://aibio.space/companies/shanghai-henlius-biotech/